We investigated the role of the eight acidic residues in the extracellular loops (exo- . Mutation of E 837 in exo-loop 3 to alanine did not alter Ca 2+ sensitivity of the full-length receptor, but in both the latter context and in Rho-C-hCaR, alanine substitution of E 837 drastically reduced sensitivity to NPS R-568. Our data point to a key role of three specific acidic residues in exo-loop 2 in hCaR activation, and to E 837 at the junction between exo-loop 3 and transmembrane helix seven in response to NPS R-568. We speculate on the basis of these results that the three acidic residues we identified in exo-loop 2 help maintain an inactive conformation of the seven transmembrane domain of the hCaR.
INTRODUCTION
] 0 is set in vivo has been documented by the identification of inactivating mutations in the CaR gene as the cause of familial hypocalciuric hypercalcemia, and activating mutations as the cause of autosomal dominant hypocalcemia (ADH) (3, 4) . Naturally occurring CaR mutations identified in subjects with ADH generally cause increased CaR sensitivity to [Ca 2+ ] 0 rather than causing constitutive activation (5) .
The CaR belongs to a unique subfamily, family 3, of G protein-coupled receptors (GPCR) with an unusually large N-terminal, extracellular domain (ECD) comprised of Venus's-flytrap (VFT) and cysteine-rich domains, in addition to the seven-transmembrane domain (7TM) characteristic of all GPCR (6) . Studies with chimeric family 3 GPCR (7-10), and the three-dimensional structure of the metabotropic glutamate type 1 receptor (mGluR1)
determined by X-ray crystallography (11) show that the VFT is the site of agonist binding in family 3 GPCR. The precise site(s) for binding to the CaR, however, have not been identified.
The activation of family 3 GPCR can also be positively modulated by compounds that bind to the 7TM domain and are presumed to act allosterically (12) . The phenylalkylamine, NPS R-568, a so-called calcimimetic, increases the sensitivity of the receptor to [Ca 2+ ] 0 activation (13) , acting as a positive allosteric modulator by binding to the CaR 7TM region (14) . A CaR mutant lacking the ECD that responds minimally to [Ca 2+ ] 0 by guest on http://www.jbc.org/ Downloaded from 4 shows significant responsiveness when NPS R-568 is added (14) . This suggests that sites involved in [Ca 2+ ] 0 activation are present within the 7TM domain and not only the ECD.
Stretches of acidic residues within the VFT have been considered likely sites of Ca 2+ binding to the CaR (15) . Given that the 7TM domain also is capable of being activated by [Ca 2+ ] 0 , we decided to investigate the role of acidic residues located in the extracellular loops of the 7TM domain in this activation. The exo-loops of the 7TM domain, like the ECD, are presumptively exposed at the cell surface, and therefore could be involved in extracellular Ca 2+ binding to and activation of the CaR.
MATERIALS AND METHODS

Site-directed mutagenesis of the hCaR
The full-length human CaR (hCaR) cDNA cloned in the pCR3.1 expression vector and a truncated receptor lacking the ECD, Rho-C-hCaR, were described previously (16, 5) .
Rho-C-hCaR contains the first 20 amino acids of the N-terminus of bovine rhodopsin fused to amino acid residues 600-903 (footnote 1) of the wild type hCaR (see Fig. 1 ). Site- ] 0 for each transfection were drawn by using GraphPad Prism version 2.0 software. Each value on a curve is the mean of duplicate determinations unless otherwise indicated. Graphs shown in this paper were representative ones from at least three independent experiments.
Synthetic Chemistry
The method for the synthesis of NPS R-568 [(R)-N-(3-methoxy-α-phenylethyl)-3-(2'-chlorophenyl)-1-propylamine hydrochloride] was reported previously (14) . For the
propylamine hydrochloride], racemic 1-(3-methoxyphenyl)ethylamine was prepared by reductive amination of 3-methoxyacetophenone with ammonium acetate (17) , and the enantiomerically pure S-isomer was isolated through crystallization with S-mandelic acid (18) . The final products were then obtained by reductive amination of 3-(2-7 chlorophenyl)propionaldehyde with the free base of S-1-(3-methoxyphenyl)ethylamine using sodium cyanoborohydride in tetrahydrofuran containing a trace of acetic acid, to provide S-568. The amine was isolated as the hydrochloric salt following treatment of the free base with anhydrous hydrochloric acid in dioxane. The specific rotations, proton NMR spectra and high resolution mass spectra were consistent with the assigned structure.
Immunoblotting and Immunocytochemistry
Confluent cells in 6-well plates were rinsed with ice-cold PBS and scraped on ice in lysis buffer containing 20 mM Tris-HCl (pH 6.8), 150 mM NaCl, 10 mM EDTA, 1 mM EGTA, 1% Triton X-100, and freshly added protease inhibitors cocktail (Boehringer 
RESULTS
Calcium response by full-length hCaR and ECD deletion mutant, Rho-C-hCaR
We previously described construction of a mutant hCaR truncated at residue 903
and with a deletion of most of the ECD (residues 1-599). The first 20 amino acids of bovine rhodopsin were fused to hCaR residue 600 to facilitate cell surface expression of this mutant construct designated Rho-C-hCaR ( -stimulated responses not only of the wild type hCaR, but also of Rho-C-hCaR (Fig. 2 ). The addition of 1 µM NPS S-568 has no effect on response to [Ca 2+ ] 0 of either WT hCaR or Rho-C-hCaR (data not shown). We found that imposing an activating mutation, F788C, identified in a subject with ADH (21) onto Rho-C-hCaR slightly increased the mutant receptor's basal activity, and mimicked the effect of NPS R-10 single band at ~36 kda for the monomeric form of the mutant receptor ( Fig. 2, right) . The immunoblot confirms the expression of Rho-C-hCaR constructs, but does not distinguish between receptor proteins expressed at the cell surface and those retained intracellularly.
The ability of Rho-C-hCaR to respond to extracellular calcium, however, indicates that at least some, if not all, of the receptor protein is expressed at the cell surface.
Assay of mutant hCaRs with acidic residues in the extracellular loops substituted by alanine
While there is strong evidence that the Venus's-flytrap (VFT) domain of the ECD of family 3 GPCRs, including the CaR, is responsible for agonist binding (7) (8) (9) (10) , the ability of Rho-C-hCaR to respond to calcium upon addition of NPS R-568 or by imposing the ] 0 but not the receptor's EC 50 value (22) . Figure 3 shows that three of the eight mutants, namely hCaR/D758A, hCaR/E759A, and hCaR/E767A, exhibited increased sensitivity to [Ca 2+ ] 0 .
The EC 50 values for these activating mutants are 0.95 ± 0.05 mM (hCaR/D758A), 0.74 ± maximal activation by calcium for mutants D758A and E759A was 50-60% of that of the WT hCaR. In contrast, alanine substitution for each of the other five acidic residues did not change the sensitivity to calcium and in most cases minimally altered maximal response.
E837A showed the lowest maximal response (~70% of WT) of these five mutants.
Because alanine substitution for several individual acidic residues within exo-loop 2 led to increased sensitivity of the CaR, we created additional mutants substituting alanine for multiple acidic residues in exo-loop 2 to determine if this would lead to further increases in CaR sensitivity. As shown in Fig. 4 ] 0 , but only to a similar extent as the individual E767A mutant.
However, changing all 5 acidic residues in exo-loop 2 to alanines simultaneously (termed hCaR/5A), not only did not lead to further increase in CaR sensitivity, but instead resulted in significantly impaired function of the receptor with maximal activation <20% of wild type hCaR (Fig. 4) . As shown by the faint upper band on immunoblot of the 5A mutant (Fig. 4, right), the loss of function of the 5A mutant is due to poor cell surface expression.
We extended our study of exo-loop 2 alanine mutants by combining these with the naturally occurring F788C mutation (hCaR/F788C) identified in subjects with ADH (21) .
In vitro study shows that this mutation causes a left-shift in the receptor's response to ] 0 -stimulated PI hydrolysis assay (Fig. 5) . Loss of receptor function was due to lack of cell surface expression as reflected in absence of the upper band on immunoblot (Fig. 5, right) .
Assay of mutant Rho-C-hCaRs with acidic residues in the extracellular loops substituted by alanines
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We next tested the effects of alanine substitution of acidic residues in the exo-loops of Rho-C-hCaR that lacks the ECD. Mutant receptor function was tested by using the intact
] 0 -stimulated PI hydrolysis assay with and without addition of 1 µM NPS R-568. 
Immunocytochemistry of cells expressing Rho-C-hCaR/5A and Rho-C-hCaR/E837A
To document whether the Rho-C-hCaR/5A and Rho-C-hCaR/E837A mutants were expressed at the cell surface, immunocytochemistry was performed with the anti-rhodopsin N-terminus antibody B6-30 whose epitope is located in the extracellular amino-terminus. (Fig. 7) , indicating that Rho-C-hCaR/5A was expressed intracellularly only.
Assay of response to NPS R-568 by hCaR/E837A
Given that the Rho-C-hCaR/E837A mutant is expressed at the cell surface and yet does not respond to [Ca 2+ ] 0 in the presence of NPS R-568, we considered the possibility that E 837 may be involved in the action of NPS R-568 on the hCaR, and that mutating this ] 0 and to NPS R-568, but since they failed to provide evidence for cell surface expression of the Rho-C-hCaR/5A mutant, this interpretation may be incorrect. Our results show that the 5A mutation both in the context of Rho-C-hCaR, and of the full-length hCaR, which Ray and Northup did not study, leads to poor cell surface expression. We did not study the response of the mutants we made to organic polycations, hence we cannot explain the basis for preservation of the poly-Larginine response of the Rho-C-hCaR/5A mutant observed by Ray and Northup, but this response is surprising given our demonstration that the Rho-C-hCaR/5A mutant is poorly expressed at the cell surface.
We observed that the Rho-C-hCaR/E837A mutant also failed to respond to [Ca 2+ ] 0 plus NPS R-568, but unlike the Rho-C-hCaR/5A mutant, immunocytochemistry clearly showed that the Rho-C-hCaR/E837A mutant is expressed at the cell surface. This ] 0 . It acts selectively on the CaR and not on related family 3 GPCR such as the mGluRs, and its site of action has been localized to the 7TM domain of the receptor (8, 14) .
Positive allosteric modulators have been identified for other family 3 GPCR such as mGluR1 (12) and GABA B receptor (28) . The site of action for the latter was not defined but for positive allosteric modulators of mGluR1, residues in the 3 rd and 5 th transmembrane helices of the 7TM domain were shown to be critical for selective response (12) . A compound acting as a noncompetitive antagonist of glutamate action on mGluR1 has also been identified (29) . Two residues, T 815 and A 818 in human mGluR1b, were shown to be critical for selective response to the noncompetitive antagonist CPCCOEt. Interestingly, these residues are located at the junction between the extracellular surface and transmembrane helix seven, and depending on exact alignment, T 815 may be the equivalent residue in human mGluR1b as E 837 in the hCaR. residues of bovine rhodopsin to hCaR residue 599 rather than 600.
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